High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms

High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms

Tumor heterogeneity is a key reason for therapeutic failure and tumor recurrence in glioblastoma (GBM). Our chimeric antigen receptor (CAR) T cell (2173 CAR T cells) clinical trial (NCT02209376) against epidermal growth factor receptor (EGFR) variant III (EGFRvIII) demonstrated successful traffickin...

Full description

Bibliographic Details
Main Authors: Radhika Thokala, Zev A. Binder, Yibo Yin, Logan Zhang, Jiasi Vicky Zhang, Daniel Y. Zhang, Michael C. Milone, Guo-li Ming, Hongjun Song, Donald M. O’Rourke
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
GBM
glioma
immunotherapy
CAR T cells
adoptive T cell therapy
EGFR
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.664236/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.664236/full

Similar Items